• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Too few patients considered candidates for treatment optimization

October 8, 2015  

Current DMTs – an overview of observational studies

October 8, 2015  

Daclizumab: DECIDE trial update

October 8, 2015  

Sequencing MS therapies: 2 studies

August 19, 2015  

Does psoriasis improve MS outcomes?

August 19, 2015  

Natalizumab in progressive MS: Phase II results

July 8, 2015  

ACTH revisited: melanocortins and MS

June 11, 2015  

Use of high-efficacy agents in MS: Updated data from AAN 2015

June 3, 2015  

Efficacy and effectiveness of first-line oral medications in MS

May 21, 2015  

Optimizing patient assessment in MS: NEDA and beyond

March 12, 2015  
Previous
27
28
29
30
31
Next

Browse by Topic

  • MS (414)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • AAN 2025 (5)
  • BIOMARKERS IN MS (54)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • DMT prescribing in Canada – survey results posted on June 6, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions